GlassScriptPhysician profile
Daniel C Maldonado
NPI 1851344949
$3,052.76
in general payments reported to CMS, 2019-2025
26 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $103 · 2021: $853 · 2022: $586 · 2023: $329 · 2024: $307 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $672.04 | 2019-2022 | |
| Novo Nordisk INC | $342.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Cvrx, INC. | $260.85 | 2022 | |
| Lilly USA, LLC | $232.02 | 2019-2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $223.80 | 2021-2024 | |
| Mannkind Corporation | $213.16 | 2019-2023 | V-Go |
| Abbott Laboratories | $186.19 | 2019-2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $125.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $122.61 | 2019-2024 | Lifevest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.35 | 2019 | |
| Pfizer INC. | $59.24 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $58.20 | 2019-2020 | |
| Abbvie INC. | $57.79 | 2019 | |
| Exact Sciences Corporation | $53.07 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $47.66 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $39.87 | 2019-2023 | |
| Glaxosmithkline, LLC. | $36.61 | 2019 | |
| Merck Sharp & Dohme LLC | $35.92 | 2019-2022 | |
| Amgen INC. | $34.13 | 2025 | Krystexxa |
| Abiomed | $30.24 | 2025 | |
| Cranial Technologies, INC | $30.12 | 2020-2021 | |
| Theratechnologies INC. | $26.12 | 2024 | Trogarzo, Egrifta |
| Dexcom, INC. | $22.45 | 2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $19.43 | 2022 | |
| Electromed, INC. | $18.27 | 2024 | Smartvest |
| Vertiflex, INC. | $16.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Maldonado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.